Although promising new therapies have emerged in clinical practice, acetylcholinesterase inhibitors and glucocorticoids remain primary treatments for MG (Arroyo, 2019; Gilhus et al., 2016). The gene discussed is ACHE; the disease is myasthenia gravis.